Abstract Details

Title Safety monitoring of alemtuzumab therapy in active relapsing multiple sclerosis: necessary, manageable but resource-intensive.

Topic Multiple Sclerosis

Presentation(s) P5 - (-)

Poster/Presentation
Number 401

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Siew Mei Yap, MBBS (National Hospital for Neurology and Neurosurgery) PRESENTER	Dr. Yap has received research support from Novartis.
Luke F. O'Donnell, MD (St. Vincent's University Hospital)	No disclosure on file
Barbara M. Carvalho (Hospital BP - Beneficencia Portuguesa de São Paulo)	Miss Carvalho has nothing to disclose.
	No disclosure on file
Nuala McNicholas, MBBS (St. Vincent'S University Hospital)	Dr. McNicholas has nothing to disclose.
Niall Tubridy, MD (St Vincent's University Hospital)	Dr. Tubridy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis .
Adrienne Visani	Ms. Visani has nothing to disclose.
	No disclosure on file